Tina E. Wood

1.4k total citations · 1 hit paper
12 papers, 1.1k citations indexed

About

Tina E. Wood is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Tina E. Wood has authored 12 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 4 papers in Cancer Research and 3 papers in Molecular Biology. Recurrent topics in Tina E. Wood's work include Pancreatic and Hepatic Oncology Research (7 papers), Neuroendocrine Tumor Research Advances (3 papers) and Cancer Genomics and Diagnostics (3 papers). Tina E. Wood is often cited by papers focused on Pancreatic and Hepatic Oncology Research (7 papers), Neuroendocrine Tumor Research Advances (3 papers) and Cancer Genomics and Diagnostics (3 papers). Tina E. Wood collaborates with scholars based in United States, Germany and Australia. Tina E. Wood's co-authors include Daniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad, Manuel Hidalgo, Lon Smith, Daniel A. Laheru, N.V. Rajeshkumar, Hui Zhang, Vuong Trieu and Neil Desai and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Tina E. Wood

12 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

2011 823 citations Daniel D. Von Hoff, Ramesh K. Ramanathan et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Tina E. Wood

Since Specialization

Citations

This map shows the geographic impact of Tina E. Wood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tina E. Wood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tina E. Wood more than expected).

Fields of papers citing papers by Tina E. Wood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tina E. Wood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tina E. Wood. The network helps show where Tina E. Wood may publish in the future.

Co-authorship network of co-authors of Tina E. Wood

This figure shows the co-authorship network connecting the top 25 collaborators of Tina E. Wood. A scholar is included among the top collaborators of Tina E. Wood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tina E. Wood. Tina E. Wood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer 2016 ·Annals of Oncology ·E. Gabriela Chiorean, Daniel D. Von Hoff, Michele Reni, Francis P. Arena, Jeffrey R. Infante, (unknown), Tina E. Wood, Paul N. Mainwaring, (unknown), P. Clingan, Volker Kunzmann, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, (unknown), Brian Lu, Andrew H. Ko	79
2	Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone 2015 ·Journal of Gastrointestinal Cancer ·Andrew M. McDonald, (unknown), (unknown), James Posey, K.S. Keene, John D. Christein, Martin J. Heslin, Tina E. Wood, Rojymon Jacob	6
3	CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC). 2013 ·Journal of Clinical Oncology ·E. Gabriela Chiorean, Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, Jeffrey R. Infante, Venu Bathini, Tina E. Wood, Paul N. Mainwaring, (unknown), Philip R. Clingan, Volker Kunzmann, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Amy Ko, Brian Lu	7
4	Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial breakdown → 2011 ·Journal of Clinical Oncology ·Daniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad, Daniel A. Laheru, Lon Smith, Tina E. Wood, Ronald L. Korn, Neil Desai, Vuong Trieu, J. L. Mesías Iglesias, Hui Zhang, Patrick Soon‐Shiong, Tao Shi, N.V. Rajeshkumar, Anirban Maitra, Manuel Hidalgo	823
5	Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5) 2010 ·Cancer Biotherapy and Radiopharmaceuticals ·Andres Forero‐Torres, Jatin J. Shah, Tina E. Wood, James Posey, (unknown), Catherine Copigneaux, Feng Luo, Slawomir Wojtowicz‐Praga, Ivor Percent, Mansoor N. Saleh	116
6	SPARC and CA19–9 as biomarkers in patients with advanced pancreatic cancer treated with nab paclitaxel plus gemcitabine 2008 ·Journal of Clinical Oncology ·Lon Smith, Ronald Drengler, Tina E. Wood, Daniel A. Laheru, Manuel Hidalgo, Mitesh J. Borad, (unknown), Daniel J. Knauer, (unknown), Daniel D. Von Hoff	2
7	Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for anal cancers: Acute toxicity profile and avoidance of a treatment break 2008 ·Journal of Clinical Oncology ·Robert Nordal, Tina E. Wood, James Posey	1
8	A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas 2008 ·Journal of Clinical Oncology ·MN Saleh, Ivor Percent, Tina E. Wood, James Posey, Jatin P. Shah, R Carlisle, Slawomir Wojtowicz‐Praga, (unknown)	25
9	Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer 2008 ·Journal of Clinical Oncology ·Ronald Drengler, Lon Smith, Tina E. Wood, Mitesh J. Borad, R. K. Ramanathan, Dan Laheru, Manuel Hidalgo, Daniel D. Von Hoff	5
10	Abstract 4179: Promising clinical activity of a NAB paclitaxel plus gemcitabine combination in a disease-specific phase I trial in patients with advanced pancreatic cancer 2008 ·Cancer Research ·Daniel D. Von Hoff, Mitesh J. Borad, Ramesh K. Ramanathan, Lon Smith, Ronald Drengler, Tina E. Wood, Daniel A. Laheru, Manuel Hidalgo	3
11	The 2-¹³C-5-fluorouracil breath test (FUBT) as a novel, rapid method for assessment of dihydropyrimidine dehydrogenase (DPD) activity in cancer patients: Initial characterization and comparison to the 2-¹³C-uracil breath test (UraBT) 2007 ·Journal of Clinical Oncology ·Jeanne Fourie, Lori K. Mattison, Tina E. Wood, James Posey, Anil Modak, Robert B. Diasio	2
12	Peripheral neuropathy associated with capecitabine 2004 ·Anti-Cancer Drugs ·Muhammad Wasif Saif, Tina E. Wood, (unknown), Robert B. Diasio	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact